Breyanzi – New CAR T-Cell therapy from BMS

Share This Post

July 2021: Breyanzi (lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (USFDA).

CAR-T cell therapy is a sort of immunotherapy that works by altering a person’s T cells to recognize and destroy cancer cells.


CAR T Cell therapy in India Cost and hospitals


Breyanzi, a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (USFDA) (lisocabtagene maraleucel; liso-cel).

Also read : CAR T-Cell therapy in India

Adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy will be treated with the new CAR T cell therapy. DLBCL not otherwise described (including DLBCL emerging from indolent lymphoma), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B are all classified as LBCL.

DLBCL cancer is the most frequent type of non-Hodgkin lymphoma (NHL), and it is an aggressive illness in which 73 percent of patients do not respond to treatment or recur.

Breyanzi, on the other hand, is not recommended for patients with primary central nervous system lymphoma, despite the fact that it is a potentially curative treatment.

Also read: CAR T-Cell therapy in China

“Breyanzi, a CAR T cell therapy, will play a crucial role in clinical practise, enabling people living with relapsed or refractory large B-cell lymphoma the possibility for a sustained response with a tailored treatment experience,” said Bristol Myers Squibb chief medical officer Samit Hirawat. Our unwavering commitment to advancing cell therapy research, providing breakthrough medicines, and supporting patients at every step of their treatment journey is reflected in the FDA approval.”

Breyanzi had a 73 percent overall response rate and a 54 percent complete response (CR) rate in the TRANSCEND NHL 001 study, which was the largest pivotal trial in 3L+ LBCL.

BMS’ immunotherapy manufacturing plant in Bothell, Washington will produce the novel cell treatment.

CAR T-Cell therapy in India is at clinical trials stage and hopefully it will be available very soon for commercial use.

Apply for CAR T-Cell therapy

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form